FRIDAY, Nov. 15, 2013 (HealthDay News) -- A device implanted within the skull to help reduce the frequency of epileptic seizures has been approved by the U.S. Food and Drug Administration.
Latest Neurology News
Epilepsy, estimated to affect nearly 3 million people in the United States, is the third most common neurological disorder behind Alzheimer's disease and stroke. Some 40 percent of those treated for epilepsy continue to have seizures, the FDA said.
Approval for the new device was based on clinical studies involving 191 people with drug-resistant epilepsy. Three months after the device was implanted, participants had about 38 percent fewer seizures per month compared to a 17 percent decrease in seizures among people who had the implanted device turned off, the FDA said. The most common adverse reactions included implant site infection and premature battery discharge.
The RNN Stimulator is produced by Neurospace Inc., based in Mountain View, Calif.
-- Scott Roberts
Copyright © 2013 HealthDay. All rights reserved.